argenx files registration statement for a proposed public offering in the United States
April 24 2017 - 1:00AM
24 April 2017
Breda, the Netherlands / Ghent,
Belgium - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage
biopharmaceutical company focused on creating and developing
differentiated therapeutic antibodies for the treatment of cancer
and severe autoimmune diseases, today announced that it filed a
registration statement on Form F-1 with the U.S. Securities and
Exchange Commission for a proposed public offering in the United
States of its American Depositary Shares (ADSs) representing
ordinary shares. All ADSs to be sold in the offering will be
offered by argenx. The offering is subject to market and other
conditions, including the effectiveness of the above-referenced
registration statement. argenx's ordinary shares are currently
listed on Euronext Brussels and argenx has made an application to
have its ADSs listed on the NASDAQ Stock Market under the symbol
"ARGX".
Cowen and Company and Piper
Jaffray & Co. are acting as joint bookrunning managers for the
proposed offering, and JMP Securities and Wedbush PacGrow are
acting as co-managers. Kempen & Co is acting as argenx's
advisor in connection with the proposed offering.
The securities referred to in this
release are to be offered only by means of a prospectus. When
available, copies of the preliminary prospectus can be obtained
from Cowen and Company, LLC, c/o Broadridge Financial Services,
1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus
Department, by telephone at (631) 274-2806 or by fax at (631)
254-7140 or from Piper Jaffray & Co., Attn: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55403, or by
telephone at (800)747-3924, or by email at
prospectus@pjc.com.
A registration statement relating
to and describing the terms of the offering has been filed with the
U.S. Securities and Exchange Commission but has not yet become
effective. The securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes
effective. This press release does not constitute an offer to sell
or the solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
About
argenx
argenx is a clinical-stage biotechnology company developing a deep
pipeline of differentiated antibody-based therapies for the
treatment of severe autoimmune diseases and cancer. We are focused
on developing product candidates with the potential to be either
first-in-class against novel targets or best-in-class against
known, but complex, targets in order to treat diseases with a
significant unmet medical need. Our ability to execute on this
focus is enabled by our suite of differentiated technologies. Our
SIMPLE Antibody(TM) Platform, based on the powerful llama immune
system, allows us to exploit novel and complex targets, and our
three antibody engineering technologies are designed to enable us
to expand the therapeutic index of our product candidates.
For further
information, please contact:
Joke Comijn, Corporate
Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@arGEN-X.com
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com
Forward-looking Statements
The contents of
this announcement include statements that are, or may be deemed to
be, "forward-looking statements". These forward-looking statements
can be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "anticipates",
"expects", "intends", "may", "will", or "should", and include
statements argenx makes concerning the intended results of its
strategy, including argenx's advancement of, and anticipated
clinical development and regulatory milestones and plans related
to, ARGX-115. By their nature, forward-looking statements involve
risks and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. argenx's actual results may differ materially from
those predicted by the forward-looking statements. argenx
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by
law.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: argenx N.V. via Globenewswire
Argen X (EU:ARGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Argen X (EU:ARGX)
Historical Stock Chart
From Apr 2023 to Apr 2024